Acute Biphenotypic Leukemia (ABL) Not Yet Recruiting Phase 2 Trials for Flotetuzumab (DB15223)

Also known as: Acute biphenotypic leukaemia / Acute Biphenotypic Leukemia / Leukemia, Biphenotypic, Acute / Acute bilineal leukemia

IndicationStatusPhase
DBCOND0081399 (Acute Biphenotypic Leukemia (ABL))Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03739606Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerTreatment